Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 13,161 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 13,161 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total value of $29,743.86. Following the completion of the sale, the insider now directly owns 485,701 shares in the company, valued at $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Ventyx Biosciences Price Performance

VTYX stock opened at $2.28 on Friday. The stock has a market capitalization of $161.22 million, a P/E ratio of -0.97 and a beta of 0.48. Ventyx Biosciences, Inc. has a 1-year low of $1.67 and a 1-year high of $11.48. The business has a fifty day moving average price of $2.30 and a 200-day moving average price of $2.40.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $10.00.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds have recently bought and sold shares of VTYX. Deerfield Management Company L.P. Series C boosted its holdings in shares of Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after acquiring an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC lifted its position in Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the period. Vestal Point Capital LP boosted its holdings in Ventyx Biosciences by 31.2% in the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after purchasing an additional 410,000 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Ventyx Biosciences in the 2nd quarter worth approximately $608,000. Finally, XTX Topco Ltd purchased a new stake in Ventyx Biosciences during the 3rd quarter valued at $246,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.